cholecalciferol and Muscle-Weakness

It is well established that activated vitamin D(3) affects bone metabolism and its bone fracture reducing effect is prominent considering relatively weak effect on increase of bone mineral density. The risk of osteoporotic bone fracture generally correlates with bone mineral density. On the other hand, fall is a major cause of bone fracture in the elderly people. Therefore, bone fracture reducing effect of activated vitamin D(3) can be presumed as the result of reduction of fall incidents (such as the effects on the stability of body balance and muscle strength), as well as the effects on bone strength and quality. In this manuscript, the relation between fall, bone fracture and vitamin D would be introduced.

Topics: Accidental Falls; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Cholecalciferol; Female; Fractures, Bone; Humans; Middle Aged; Muscle Weakness; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors

We recorded the manifestations of severe vitamin D deficiency (VDD) in 40 adolescents before and 3 and 6 months after treatment with a mega dose of cholecalciferol (10 000 IU kg(-1), max 600 000 IU). Significant improvement of symptoms related to VDD was reported in 34/40. Three months after the injection, serus calcium, phosphate, alkaline phosphatase and parathormone were normal in all adolescents with VDD with 25-hydroxyvitamin D (25OHD) level = or >20 ng ml(-1). After 6 months, the majority had 25OHD level <20 ng ml(-1). Two patterns of radiological changes have been recorded with complete healing achieved in all patients after a year of therapy. A mega dose of cholecalciferol is an effective therapy for treatment of VDD in adolescents for 3 months but not for 6 months. Radiographs of the ends of long bones are still valuable tool for diagnosis and follow-up of these patients.

Topics: Adolescent; Alkaline Phosphatase; Arthralgia; Back Pain; Biomarkers; Bone Density Conservation Agents; Calcium; Cholecalciferol; Female; Humans; Injections, Intramuscular; Knee; Male; Muscle Weakness; Parathyroid Hormone; Phosphorus; Prospective Studies; Qatar; Radiography; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome; Vitamin D Deficiency; Walking; Wrist

Fragility fractures are a major burden for health and social care in elderly people. In order to identify earlier the "frail elders", new concepts of "dysmobility syndrome" and skeletal muscle function deficit (SMFD), including sarcopenia, osteoporosis, obesity, and mobility limitation, leading to a higher risk of fractures, have been recently introduced. There are very few studies investigating the association between fragility fractures and both the dysmobility syndrome and the SMFD.. The objective of our study is to investigate the role of previous fragility fractures as a risk factor in determining the dysmobility syndrome and/or the SMFD in post-menopausal women.. In this case-control study, we retrospectively examined data from the medical records of post-menopausal women aged 50 or older. We divided the study population in two groups. The first group includes women with a previous fragility fracture (cases) and the other group includes women without any previous osteoporotic fracture (controls). We identified the subjects with "dysmobility syndrome", "dynapenic SMFD", "sarcopenic SMFD", and "mixed SMFD" in both groups. Data collected refer to a 6-month period.. We retrieved data of 121 post-menopausal women, 77 (63.64%) had already sustained a fragility fracture at any site (cases). The risk for dysmobility syndrome was significantly higher (adjusted OR for age and serum 25-OH vitamin D3 of 2.46) in the cases compared with the controls.. An early diagnosis of conditions limiting mobility, including dysmobility syndrome, might be useful to identify, among patients with osteoporotic fractures, those who might have a higher risk of a new fragility fracture.

Topics: Aged; Aged, 80 and over; Bone Density; Case-Control Studies; Cholecalciferol; Female; Frail Elderly; Humans; Italy; Mobility Limitation; Muscle Weakness; Muscle, Skeletal; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prevalence; Risk Assessment; Risk Factors; Sarcopenia; Syndrome

We report a 28-year-old woman who presented with severe proximal muscle weakness secondary to paraneoplastic hypophosphatemia and associated with recurrent neuroblastoma. The biochemical findings included hyperphosphaturia, a reduced serum level of 1,25-dihydroxyvitamin-D3, elevated alkaline phosphatase and normocalcemia which are pathognomic for paraneoplastic hypophosphatemia. Following systemic chemotherapy and supplementation of 1,25-dihydroxyvitamin-D3 a complete remission of the neuroblastoma was achieved and all features of the paraneoplastic hypophosphatemia gradually disappeared. In the differential diagnosis of muscle weakness, hypophosphatemia should be included. Paraneoplastic hypophosphatemia associated with metastatic neuroblastoma has not been reported previously. Diagnosis, mechanism and therapy of paraneoplastic hypophosphatemia are shortly reviewed.

Topics: Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcium; Cholecalciferol; Female; Follow-Up Studies; Humans; Hypophosphatemia; Magnetic Resonance Imaging; Muscle Weakness; Neoplasm Recurrence, Local; Neuroblastoma; Paraneoplastic Syndromes; Spinal Neoplasms